Literature DB >> 32053511

Relevance of TNF-α, IL-6 and IRAK1 gene expression for assessing disease severity and therapy effects in tuberculosis patients.

Ivana Buha1, Vesna Škodrić-Trifunović2, Tatjana Adžić-Vukičević3, Aleksandra Ilić4, Ana Blanka-Protić5, Mihailo Stjepanovic6, Marina Anđelković7, Miša Vreća8, Jelena Milin-Lazović9, Vesna Spasovski10, Sonja Pavlović11.   

Abstract

INTRODUCTION: Tuberculosis (TBC) is a contagious chronic respiratory disease which despite the known cause, Mycobacterium tuberculosis (Mtb), and many decades of successful therapy, remains one of the leading global health problems. Immune responses against Mtb infection involve both of types of immunity, but cellular immunity, in which certain cytokines and Th1 cells play a key role, is crucial. A better understanding of the functions of the cytokine network involved in the state and progression of TBC could identify specific molecular markers for monitoring of disease activity as well as therapy outcomes in TBC patients.
METHODOLOGY: We investigated expression of TNF-α, IL-6 and IRAK1 genes using an RT-qPCR technique in peripheral blood mononuclear cells of 33 TBC patients and 10 healthy individuals.
RESULTS: Comparison between TBC patients and healthy individuals revealed statistically significant differences for all analyzed genes. The levels of expression of TNF-α and IL-6 mRNA were higher, while the level of IRAK1 mRNA was lower in the TBC group compared to controls. Moreover, a strong positive correlation was observed between TNF-α and IL-6 gene expression. When clinical parameters were analyzed, increased levels of TNF-α mRNA were detected in patients with a longer duration of therapy (>2 months) compared to those with a shorter therapy duration (< 2 months), and in patients without anemia.
CONCLUSIONS: Our results indicate that the inflammatory genes we examined play a crucial role in the pathogenesis of tuberculosis, and that the expression of the TNF-α gene could be a marker for monitoring the clinical effect of the ant-tuberculosis drugs during therapy. Copyright (c) 2019 Ivana Buha, Vesna Skodric-Trifunovic, Tatjana Adzic-Vukicevic, Aleksandra Ilic, Ana Blanka-Protic, Mihailo Stjepanovic, Marina Andelkovic, Misa Vreca, Jelena Milin-Lazovic, Vesna Spasovski, Sonja Pavlovic.

Entities:  

Keywords:  cytokines; gene expression; monitoring therapy; pulmonary tuberculosis

Year:  2019        PMID: 32053511     DOI: 10.3855/jidc.10949

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  5 in total

Review 1.  The Role of gp130 Cytokines in Tuberculosis.

Authors:  Kristina Ritter; Jasmin Rousseau; Christoph Hölscher
Journal:  Cells       Date:  2020-12-15       Impact factor: 6.600

2.  Pleiotropic Effect of IL-6 Produced by B-Lymphocytes During Early Phases of Adaptive Immune Responses Against TB Infection.

Authors:  Irina Linge; Anastasiya Tsareva; Elena Kondratieva; Alexander Dyatlov; Juan Hidalgo; Ruslan Zvartsev; Alexander Apt
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

3.  Restricted Activation of the NF-κB Pathway in Individuals with Latent Tuberculosis Infection after HIF-1α Blockade.

Authors:  Aline de Oliveira Rezende; Rafaella Santos Sabóia; Adeliane Castro da Costa; Diana Messala Pinheiro da Silva Monteiro; Adrielle Zagmignan; Luis Ângelo Macedo Santiago; Rafael Cardoso Carvalho; Paulo Vitor Soeiro Pereira; Ana Paula Junqueira-Kipnis; Eduardo Martins de Sousa
Journal:  Biomedicines       Date:  2022-03-31

4.  Associations between serum amyloid A, interleukin-6, and COVID-19: A cross-sectional study.

Authors:  Qian Liu; Yaping Dai; Meimei Feng; Xu Wang; Wei Liang; Fumeng Yang
Journal:  J Clin Lab Anal       Date:  2020-08-28       Impact factor: 2.352

5.  The Angiopoietin-like protein 4: a promising biomarker to distinguish brucella spondylitis from tuberculous spondylitis.

Authors:  Siqin Lan; Yuanlin He; Maijudan Tiheiran; Wenya Liu; Hui Guo
Journal:  Clin Rheumatol       Date:  2021-05-06       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.